JBIO Jade Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ 10-K/10-Q Aug 10, 2026
$14.59
· of 52w range
· above low
· to high
$8.3652w low
$28.0052w high
Market Cap (MRQ)
$927M
P/E
-4.6
EPS
$-3.19
your badges
52W Range
$8–$28
Analyst Rating
STRONG BUY
Price Target
$50
P/E
-4.6
ROE
-47.7%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
JBIO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$14.59
Market Cap (MRQ)
$927M
P/E
-4.6
EPS
$-3.19
ROE
-47.7%
52W Range
$8–$28
JBIO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| April 29, 2025 | 1-for-35 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-3.192021-12-31 → 2025-12-31
Free Cash Flow$-95M2021-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | JBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -4.65Y avg ≈-205.6 | ≈-205.6 | · | · | |
| P/B (MRQ) | 2.15Y avg ≈99.4 | ≈99.4 | 3.9 | Undervalued | |
| Price / FCF | -7.65Y avg ≈-351.1 | ≈-351.1 | · | · | |
| Price / Cash Flow | -7.65Y avg ≈-289.8 | ≈-289.8 | · | · | |
| Price / Tangible Book | 2.25Y avg ≈115.4 | ≈115.4 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | JBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -60.3%5Y avg ≈-48.7% | ≈-48.7% | -42.8% | Weak | |
| ROE | -47.7%5Y avg ≈-79.5% | ≈-79.5% | -29.7% | Weak | |
| ROIC | -34.2%5Y avg ≈-52.3% | ≈-52.3% | -56.1% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | JBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 14.95Y avg ≈26.9 | ≈26.9 | 10.6 | Strong liquidity | |
| Quick Ratio | 20.35Y avg ≈26.0 | ≈26.0 | 8.2 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Apr 29, 2025 | $2.40 | USD | ≈23.7% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-9.4%
Next Report
Nov 11, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 11, 2026 | $-0.76 | $-0.65 | -17.2% |
| March 31, 2026 | $-0.57 | $-0.49 | -15.8% | |
| Dec. 31, 2025 | $-0.59 | $-0.48 | -22.0% | |
| Sept. 30, 2025 | $-0.48 | $-0.69 | 30.2% | |
| June 30, 2025 | $-0.86 | $-0.44 | -94.8% | |
| March 31, 2025 | $-3.15 | $-8.57 | 63.2% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $93M | $53M | $64M | $39M | $15M | $8M | |
| SG&A Expense | $20M | $21M | $17M | $15M | $8M | $949.0K | |
| Operating Expenses | $114M | $75M | $81M | $53M | $23M | $9M | |
| Operating Income | $-114M | $-75M | $-81M | $-53M | $-23M | $-9M | |
| Interest Expense | · | · | · | · | · | $75.0K | |
| Other Non-op | $-8.0K | $-19.0K | $-1.0K | $2M | $62.0K | $-722.0K | |
| Pretax Income | $-127M | $-70M | $-75M | $-51M | $-23M | $-10M | |
| Income Tax | $58.0K | $55.0K | $56.0K | $25.0K | $3.0K | · | |
| Net Income | $-127M | $-70M | $-76M | $-52M | $-23M | $-10M | |
| EPS (Basic) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 | · | |
| EPS (Diluted) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 | · | |
| Shares (Basic) | 31,359,958 | 28,582,194 | 26,331,630 | 24,472,104 | 12,293,629 | · | |
| Shares (Diluted) | 31,359,958 | 28,582,194 | 26,331,630 | 24,472,104 | 12,293,629 | · | |
| EBITDA | $-114M | $-75M | $-81M | $-53M | $-23M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $88M | $69M | $23M | $22M | $54M | $5M | |
| Short-term Investments | $248M | $0 | $99M | $107M | $113M | · | |
| Prepaid Expense | $13M | $268.0K | $2M | $2M | $7M | $103.0K | |
| Current Assets | $349M | $70M | $124M | $131M | $174M | $5M | |
| PP&E (Net) | $170.0K | · | $288.0K | $242.0K | $186.0K | $39.0K | |
| PP&E (Gross) | · | · | · | · | · | $40.0K | |
| Accum. Depreciation | · | · | · | · | · | $1.0K | |
| Other Non-current Assets | $69.0K | $3M | $2M | $3M | $302.0K | · | |
| Total Assets | $350M | $73M | $127M | $135M | $175M | $5M | |
| Accounts Payable | $2M | $1M | $2M | $3M | $1M | $618.0K | |
| Accrued Liabilities | $9M | $4M | · | · | · | · | |
| Current Liabilities | $17M | $12M | $18M | $8M | $3M | $2M | |
| Capital Leases | $724.0K | $0 | $255.0K | $705.0K | $382.0K | · | |
| Total Liabilities | $17M | $120M | $18M | $9M | $3M | $2M | |
| Common Stock | $5.0K | $1.0K | $3.0K | $2.0K | $2.0K | · | |
| Paid-in Capital | $507M | $179.0K | $273M | $215M | $209M | $63.0K | |
| Retained Earnings | $-174M | $-47M | $-163M | $-88M | $-36M | $-13M | |
| AOCI | $129.0K | $0 | $237.0K | $-466.0K | $-59.0K | · | |
| Stockholders' Equity | $333M | $-47M | $109M | $127M | $172M | $-13M | |
| Liabilities + Equity | $350M | $73M | $127M | $135M | $175M | $5M | |
| Shares Outstanding | 49,316,287 | 3,672,794 | 27,762,703 | 24,722,974 | 24,410,393 | 243,076 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $20M | $11M | $12M | $5M | $2M | $58.0K | |
| Deferred Tax | $-44.0K | · | · | · | · | · | |
| Operating Cash Flow | $-95M | $-71M | $-57M | $-39M | $-27M | $-8M | |
| CapEx | $196.0K | · | $142.0K | $195.0K | $181.0K | · | |
| Investing Cash Flow | $-247M | $56M | $12M | $7M | $-113M | · | |
| Stock Issued | · | $24M | $45M | · | $127M | · | |
| Net Stock Activity | · | $24M | $45M | · | $127M | · | |
| Financing Cash Flow | $361M | $25M | $46M | $396.0K | $190M | $9M | |
| Net Change in Cash | $19M | $10M | $1M | $-32M | $50M | $1M | |
| Free Cash Flow | $-95M | · | $-57M | $-39M | $-28M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -60.3% | -67.0% | -57.5% | -33.2% | -25.5% | · | |
| ROE | -47.7% | -233.8% | -64.2% | -38.8% | -13.0% | · | |
| ROIC | -34.2% | -97.7% | -74.4% | -42.0% | -13.4% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 21.1 | 20.9 | 7.0 | 16.9 | 68.4 | · | |
| Quick Ratio | 20.3 | 20.5 | 6.9 | 16.6 | 65.6 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.74 | $2.64 | $3.94 | $5.13 | $7.06 | · | |
| Cash Flow / Share | $-3.02 | $-2.49 | $-2.16 | $-1.60 | · | · | |
| Cash / Share | $1.79 | $1.16 | $0.85 | $0.91 | $2.22 | · | |
| EPS (TTM) | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-127M | $-70M | $-76M | $-52M | $-23M | · | |
| Market Cap | $761M | $2.69B | $21.99B | $25.35B | $10.07B | · | |
| P/E | -4.8 | -38.0 | -276.0 | -488.3 | -220.7 | · | |
| P/B | 2.3 | 35.2 | 200.9 | 200.0 | 58.4 | · | |
| P / Tangible Book | 2.3 | · | 200.9 | 200.0 | 58.4 | · | |
| P / Cash Flow | -8.0 | -37.8 | -387.3 | -648.1 | -367.6 | · | |
| P / FCF | -8.0 | · | -386.3 | -644.8 | -365.2 | · | |
| Earnings Yield | -20.7% | -2.6% | -0.36% | -0.20% | -0.45% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $50M | $36M | $29M | $22M | $23M | $20M | $-2M | $14M | $21M | $20M | $18M | $17M | $16M | $13M | $12M | $11M | |
| SG&A Expense | $9M | $7M | $6M | $5M | $5M | $3M | $11M | $1M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | |
| Operating Expenses | $59M | $43M | $55M | $27M | $28M | $23M | $9M | $15M | $26M | $25M | $22M | $21M | $20M | $18M | $16M | $14M | |
| Operating Income | $-59M | $-43M | $-55M | $-27M | $-28M | $-23M | $-9M | $-15M | $-26M | $-25M | $-22M | $-21M | $-20M | $-18M | $-16M | $-14M | |
| Other Non-op | $-62.0K | $-9.0K | $4M | $-28.0K | $0 | $0 | $-1M | $0 | $1M | $-3.0K | $-2M | $1.0K | $1M | $1M | $2M | $4.0K | |
| Pretax Income | $-56M | $-40M | · | · | $-32M | $-38M | · | · | · | · | · | · | · | · | · | · | |
| Income Tax | $15.0K | $16.0K | $58.0K | $0 | $0 | · | · | $0 | · | · | · | · | · | · | · | · | |
| Net Income | $-56M | $-40M | $-32M | $-25M | $-32M | $-38M | $-5M | $-16M | $-25M | $-23M | $-20M | $-20M | $-19M | $-17M | $-15M | $-14M | |
| EPS (Basic) | $-0.76 | $-0.57 | $-1.76 | $-0.48 | $-0.86 | $-12.10 | $4.41 | $-5.16 | $-0.86 | $-0.83 | $-0.73 | $-0.71 | $-0.76 | $-0.67 | $-0.60 | $-0.56 | |
| EPS (Diluted) | $-0.76 | $-0.57 | $-1.76 | $-0.48 | $-0.86 | $-12.10 | $4.41 | $-5.16 | $-0.86 | $-0.83 | $-0.73 | $-0.71 | $-0.76 | $-0.67 | $-0.60 | $-0.56 | |
| Shares (Basic) | 61,050,775 | 57,777,165 | · | 39,584,489 | 28,431,158 | 3,155,500 | · | 3,155,500 | 28,756,043 | 27,795,827 | · | 27,640,542 | 25,166,505 | 24,777,847 | · | 24,454,786 | |
| Shares (Diluted) | 61,050,775 | 57,777,165 | · | 39,584,489 | 28,431,158 | 3,155,500 | · | 3,155,500 | 28,756,043 | 27,795,827 | · | 27,640,542 | 25,166,505 | 24,777,847 | · | 24,454,786 | |
| EBITDA | $-59M | $-43M | · | $-27M | $-28M | $-3M | · | $-17M | $-26M | $-25M | · | $-21M | $-20M | $-18M | · | $-14M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $107M | $55M | $88M | $50M | $221M | $44M | $34M | $31M | $31M | $9M | $23M | $32M | $61M | $27M | $22M | $22M | |
| Short-term Investments | $354M | $256M | $248M | $149M | · | $32M | $45M | $58M | $73M | $90M | $99M | $103M | $89M | $92M | $107M | $120M | |
| Prepaid Expense | $10M | $7M | $13M | $2M | $2M | $1M | $1M | $2M | $7M | $4M | $2M | $2M | $2M | $2M | $2M | $3M | |
| Current Assets | $471M | $319M | $349M | $201M | $223M | $77M | $80M | $91M | $111M | $103M | $124M | $138M | $152M | $121M | $131M | $145M | |
| PP&E (Net) | $144.0K | $157.0K | $170.0K | $176.0K | $147.0K | $2.0K | $6.0K | $14.0K | $232.0K | $260.0K | $288.0K | $316.0K | $245.0K | $267.0K | $242.0K | $330.0K | |
| Other Non-current Assets | $69.0K | $69.0K | $69.0K | $174.0K | $60.0K | · | · | $81.0K | $81.0K | $3M | $2M | $2M | $2M | $3M | $3M | $1M | |
| Total Assets | $472M | $319M | $350M | $202M | $224M | $78M | $80M | $91M | $112M | $107M | $127M | $141M | $156M | $124M | $135M | $148M | |
| Accounts Payable | $7M | $4M | $2M | $1M | $8M | $69.0K | $224.0K | $908.0K | $4M | $3M | $2M | $4M | $6M | $5M | $3M | $5M | |
| Accrued Liabilities | $15M | $15M | $9M | $14M | $8M | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $32M | $22M | $17M | $22M | $22M | $2M | $4M | $10M | $17M | $16M | $18M | $15M | $13M | $11M | $8M | $8M | |
| Capital Leases | $628.0K | $679.0K | $724.0K | $747.0K | $792.0K | · | · | $81.0K | $206.0K | $329.0K | $255.0K | $358.0K | $476.0K | $591.0K | $705.0K | $800.0K | |
| Total Liabilities | $32M | $23M | $17M | $23M | $22M | $2M | $4M | $10M | $17M | $16M | $18M | $15M | $14M | $11M | $9M | $9M | |
| Common Stock | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | |
| Paid-in Capital | $711M | $512M | $507M | $322M | $319M | $311M | $309M | $308M | $306M | $278M | $273M | $269M | $266M | $218M | $215M | $213M | |
| Retained Earnings | $-271M | $-215M | $-174M | $-142M | $-117M | $-236M | $-233M | $-228M | $-211M | $-187M | $-163M | $-143M | $-123M | $-104M | $-88M | $-73M | |
| AOCI | $-660.0K | $-342.0K | $129.0K | $29.0K | $-24.0K | $50.0K | $105.0K | $224.0K | $-83.0K | $-33.0K | $237.0K | $-195.0K | $-223.0K | $-201.0K | $-466.0K | $-771.0K | |
| Stockholders' Equity | $440M | $296M | $333M | $179M | $202M | $75M | $76M | $80M | $94M | $91M | $109M | $126M | $142M | $113M | $127M | $139M | |
| Liabilities + Equity | $472M | $319M | $350M | $202M | $224M | $78M | $80M | $91M | $112M | $107M | $127M | $141M | $156M | $124M | $135M | $148M | |
| Shares Outstanding | 63,556,065 | 49,345,967 | 49,316,287 | 32,626,730 | 32,626,730 | 28,985,019 | 28,985,019 | 28,867,711 | 28,854,750 | 27,898,761 | 27,762,703 | 27,653,187 | 27,601,098 | 24,816,940 | 24,722,974 | 24,506,390 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $14M | $7M | $11M | $4M | $4M | $2M | $3M | $27.0K | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Operating Cash Flow | $-44M | $-24M | $-34M | $-22M | $-37M | $-19M | $-11M | $-7M | $-20M | $-24M | $-15M | $-16M | $-15M | $-11M | $-15M | $-10M | |
| CapEx | · | · | $3.0K | $57.0K | · | · | · | · | · | · | $64.0K | $32.0K | $30.0K | $16.0K | $4.0K | $33.0K | |
| Investing Cash Flow | $-98M | $-8M | $-98M | $-149M | $-13M | $13M | $13M | $0 | $18M | $9M | $6M | $-13M | $4M | $15M | $14M | $5M | |
| Stock Issued | · | · | · | · | · | · | $307.0K | $0 | · | · | $0 | $0 | · | · | · | · | |
| Financing Cash Flow | $194M | $-795.0K | $170M | $0 | $191M | $-700.0K | $554.0K | $95M | $24M | $471.0K | $463.0K | $20.0K | $45M | $223.0K | $357.0K | $37.0K | |
| Net Change in Cash | $52M | $-33M | $38M | $-171M | $141M | $-19M | $3M | $88M | $22M | $-14M | $-9M | $-29M | $34M | $4M | $-22.0K | $-5M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-11M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -16.0% | -20.3% | · | -17.2% | -19.1% | -2.7% | · | -14.0% | -18.5% | -20.1% | · | -13.6% | -12.2% | -11.3% | · | -8.2% | |
| ROE | -17.4% | -21.7% | · | -19.4% | -21.7% | -3.0% | · | -15.8% | -21.0% | -22.7% | · | -14.8% | -13.0% | -12.0% | · | -8.5% | |
| ROIC | -13.4% | -14.7% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.9 | 14.3 | · | 9.0 | 10.3 | 32.0 | · | 8.8 | 6.5 | 6.7 | · | 9.3 | 11.5 | 11.3 | · | 18.8 | |
| Quick Ratio | 14.6 | 14.0 | · | 8.9 | 10.2 | 31.5 | · | 8.6 | 6.1 | 6.4 | · | 9.2 | 11.3 | 11.2 | · | 18.5 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.92 | $6.01 | · | $5.50 | $6.18 | $2.59 | · | $2.79 | $3.27 | $3.26 | · | $4.55 | $5.14 | $4.56 | · | $5.68 | |
| Cash Flow / Share | · | $-0.42 | · | · | · | $-0.08 | · | · | · | $-0.85 | · | · | · | $-0.46 | · | · | |
| Cash / Share | $1.69 | $1.12 | · | $1.54 | $6.77 | $1.53 | · | $1.08 | $1.08 | $0.33 | · | $1.16 | $2.21 | $1.07 | · | $0.91 | |
| EPS (TTM) | $-3.57 | $-3.67 | · | $-9.03 | $-13.71 | $-13.71 | · | $-7.58 | $-3.13 | $-3.03 | · | $-2.74 | $-2.59 | $-2.32 | · | $-1.57 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-153M | $-130M | · | $-101M | $-92M | $-85M | · | $-85M | $-88M | $-82M | · | $-70M | $-64M | $-57M | · | $-45M | |
| Market Cap | $1.41B | $693M | · | $282M | $326M | $2.55B | · | $2.11B | $1.68B | $28.87B | · | $13.13B | $16.57B | $17.52B | · | $14.22B | |
| P/E | -6.2 | -3.8 | · | -1.0 | -0.7 | -6.4 | · | -9.7 | -18.6 | -341.6 | · | -173.3 | -231.8 | -304.3 | · | -369.6 | |
| P/B | 3.2 | 2.3 | · | 1.6 | 1.6 | 33.9 | · | 26.2 | 17.8 | 317.6 | · | 104.5 | 116.7 | 154.9 | · | 102.2 | |
| P / Tangible Book | 3.2 | 2.3 | · | 1.6 | 1.6 | 33.9 | · | 26.2 | 17.8 | 317.6 | · | 104.5 | 116.7 | 154.9 | · | 102.2 | |
| P / Cash Flow | · | -28.8 | · | · | · | -1069.4 | · | · | · | -1219.7 | · | · | · | -1533.6 | · | · | |
| Earnings Yield | -16.1% | -26.1% | · | -104.6% | -137.2% | -15.6% | · | -10.4% | -5.4% | -0.29% | · | -0.58% | -0.43% | -0.33% | · | -0.27% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Net Income | $-127M | $-70M | $-76M | $-52M | $-23M |
| Diluted EPS | $-3.19 | $-2.44 | $-2.87 | $-2.10 | $-1.87 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 21.1 | 20.9 | 7.0 | 16.9 | 68.4 |
| Quick Ratio | 20.3 | 20.5 | 6.9 | 16.6 | 65.6 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-95M | · | $-57M | $-39M | $-28M |
Institutional owners (13F) 157 filers · $1.6B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
157
Value held
$1.6B
New positions
52
Exited positions
16
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 52 (+18 vs prior Q) | 16 (+5 vs prior Q) | 61 (+24 vs prior Q) | 24 (-8 vs prior Q) | +16.8M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| FMR LLC | $202,799,207 | 9,126,877 | 13.07% | Shares |
| Fairmount Funds Management LLC | $101,178,637 | 4,553,494 | 6.52% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $81,571,464 | 3,671,083 | 5.26% | Shares |
| Venrock Adviser, LLC | $71,556,488 | 3,220,364 | 4.61% | Shares |
| Bellevue Group AG | $67,948,671 | 3,057,996 | 4.38% | Shares |
| Paradigm Biocapital Advisors LP | $63,491,539 | 2,857,405 | 4.09% | Shares |
| BlackRock, Inc. | $62,248,241 | 2,801,451 | 4.01% | Shares |
| FRANKLIN RESOURCES INC | $62,040,028 | 2,792,080 | 4.00% | Shares |
| STATE STREET CORP | $51,890,033 | 2,335,285 | 3.34% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $49,878,856 | 2,244,773 | 3.21% | Shares |
| JANUS HENDERSON GROUP PLC | $43,557,008 | 3,105,669 | 2.81% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $42,458,243 | 1,910,812 | 2.74% | Shares |
| Polar Capital Holdings Plc | $41,039,940 | 1,846,982 | 2.64% | Shares |
| Avidity Partners Management LP | $37,789,732 | 1,700,708 | 2.43% | Shares |
| Remedium Capital Partners, LLC | $35,057,605 | 1,577,750 | 2.26% | Shares |
| Soleus Capital Management, L.P. | $34,456,332 | 1,550,690 | 2.22% | Shares |
| JPMORGAN CHASE & CO | $32,613,997 | 1,475,079 | 2.10% | Shares |
| VANGUARD GROUP INC | $32,337,685 | 2,095,767 | 2.08% | Shares |
| BAKER BROS. ADVISORS LP | $27,340,066 | 1,230,426 | 1.76% | Shares |
| Logos Global Management LP | $24,997,500 | 1,125,000 | 1.61% | Shares |
| Versant Venture Management, LLC | $22,037,418 | 991,783 | 1.42% | Shares |
| ACORN CAPITAL ADVISORS, LLC | $21,925,807 | 986,760 | 1.41% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $21,896,658 | 985,178 | 1.41% | Shares |
| CITADEL ADVISORS LLC | $20,651,423 | 929,407 | 1.33% | Shares |
| Foresite Capital Management VI LLC | $19,701,741 | 886,667 | 1.27% | Shares |
| Balyasny Asset Management L.P. | $19,525,292 | 878,726 | 1.26% | Shares |
| Affinity Asset Advisors, LLC | $18,672,577 | 840,350 | 1.20% | Shares |
| SAMSARA BIOCAPITAL, LLC | $16,359,186 | 736,237 | 1.05% | Shares |
| GOLDMAN SACHS GROUP INC | $16,336,678 | 735,224 | 1.05% | Shares |
| Pictet Asset Management Holding SA | $16,304,325 | 733,768 | 1.05% | Shares |
| Aberdeen Group plc | $13,801,020 | 621,108 | 0.89% | Shares |
| MARSHALL WACE, LLP | $13,015,609 | 585,761 | 0.84% | Shares |
| BANK OF AMERICA CORP /DE/ | $10,820,140 | 486,955 | 0.70% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $10,255,152 | 461,528 | 0.66% | Shares |
| Blackstone Inc. | $9,672,810 | 435,320 | 0.62% | Shares |
| Ikarian Capital, LLC | $9,495,694 | 427,349 | 0.61% | Shares |
| Walleye Capital LLC | $8,116,344 | 365,272 | 0.52% | Shares |
| MILLENNIUM MANAGEMENT LLC | $6,989,257 | 314,548 | 0.45% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $6,774,145 | 304,867 | 0.44% | Shares |
| NORTHERN TRUST CORP | $6,556,700 | 295,081 | 0.42% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $4,825,229 | 217,157 | 0.31% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $4,431,312 | 199,429 | 0.29% | Shares |
| Jump Financial, LLC | $3,838,439 | 172,747 | 0.25% | Shares |
| Point72 Asset Management, L.P. | $3,715,273 | 167,204 | 0.24% | Shares |
| Russell Investments Group, Ltd. | $3,623,746 | 163,084 | 0.23% | Shares |
| Opaleye Management Inc. | $3,221,900 | 145,000 | 0.21% | Shares |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $3,114,989 | 140,886 | 0.20% | Shares |
| UBS Group AG | $2,834,761 | 127,577 | 0.18% | Shares |
| MORGAN STANLEY | $2,766,679 | 124,513 | 0.18% | Shares |
| Quantinno Capital Management LP | $2,548,990 | 114,716 | 0.16% | Shares |
Activists & 5%+ owners 5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest IV L.P., Peter Evan Harwin, Tomas Kiselak ×3 filings | June 9, 2026 | 19.99% | Amendment | · | SEC |
| Sofinnova Venture Partners X, L.P. ("SVP X"), Sofinnova Management X, L.P. ("SM X LP"), Sofinnova Management X-A, L.L.C. ("SM X LLC"), Dr. James I. Healy ("Healy"), Dr. Maha Katabi ("Katabi") | March 5, 2026 | 0.30% | Amendment | Passive investment | SEC |
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×5 filings | April 30, 2025 | 4.10% | Amendment | · | SEC |
| Atlas Venture Fund XII, L.P., Atlas Venture Associates XII, L.P., Atlas Venture Associates XII, LLC ×5 filings | April 30, 2025 | 0.20% | Amendment | M&A / sale | SEC |
| Sofinnova Venture Partners X, L.P. (“SVP X”), Sofinnova Management X, L.P. (“SM X LP”), Sofinnova Management X-A, L.L.C. (“SM X LLC”), Dr. James I. Healy (“Healy”), Dr. Maha Katabi (“Katabi”) ×3 filings | Feb. 20, 2024 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 24 insiders · 11 officers · 14 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Tom Frohlich | Chief Executive Officer | Feb. 12, 2026 A | 86,331 | 0 | 0 | $0 |
| Timothy P Noyes | CHIEF EXECUTIVE OFFICER | May 16, 2024 M | 0 | 0 | 0 | $0 |
| Bradford D. Dahms | Chief Financial Officer | Feb. 12, 2026 A | 37,813 | 0 | 0 | $0 |
| George A Eldridge | Officer Title: Chief Financial Officer and Treasurer | June 14, 2024 M | 5,022 | 0 | 0 | $0 |
| Benjamin T Dake | Officer Title: President, Chief Operating Officer and Secretary | Aug. 1, 2024 M | 14,252 | 0 | 0 | $0 |
| Elizabeth Balta | Chief Legal Officer and Corporate Secretary | Feb. 12, 2026 A | 28,125 | 0 | 0 | $0 |
| Andrew James King | Chief Scientific Officer & Head of Research and Development | Feb. 12, 2026 A | 386,113 | 0 | 0 | $0 |
| Marinus Verwijs | CHIEF TECHNICAL OFFICER | June 14, 2024 M | 0 | 0 | 0 | $0 |
| Hunter Gillies | CHIEF MEDICAL OFFICER | June 13, 2024 M | 5,602 | 0 | 0 | $0 |
| Ralph Niven | CHIEF SCIENTIFIC OFFICER | Feb. 5, 2024 M | 1,609 | 0 | 0 | $0 |
| Timothy Pigot | CHIEF COMMERCIAL OFFICER | Jan. 22, 2024 A | · | 0 | 0 | $0 |
| Mark Eisner | Director | June 25, 2026 A | · | 0 | 0 | $0 |
| Christopher W. Cain | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Lawrence Otto Klein | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Erin Lavelle | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Eric Dobmeier | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| David S. Grayzel | Director | June 5, 2024 A | 14,502 | 0 | 0 | $0 |
| Dr. Maha Katabi | Director | June 5, 2024 A | 3,758,686 | 0 | 0 | $0 |
| Joshua Resnick | Director | June 5, 2024 A | · | 0 | 0 | $0 |
| Habib J Dable | Director | June 5, 2024 A | · | 0 | 0 | $0 |
| Allison Dorval | Director | June 5, 2024 A | · | 0 | 0 | $0 |
| Mark T Iwicki | Director | June 5, 2024 A | · | 0 | 0 | $0 |
| Donald J Santel | Director | June 5, 2024 A | · | 0 | 0 | $0 |
| Atlas Venture Fund XII, L.P. | 10% owner | July 15, 2022 J | 2,327,909 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 19 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.86% | 20,261 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.21% | 52,113 NS | July 31, 2026 | N-PORT |
| IWC · iShares Trust | 0.15% | 110,135 SH | Sept. 11, 2026 | Daily |
| FFSM · FIDELITY COVINGTON TRUST | 0.12% | 93,021 NS | July 31, 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.12% | 111,509 SH | Aug. 19, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.06% | 712 NS | July 31, 2026 | N-PORT |
| IWO · iShares Trust | 0.04% | 305,709 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 34,886 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.02% | 836,516 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 187,416 SH | Aug. 19, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 19,767 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 489,225 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 124,984 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 2,568 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 71,131 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 15,055 SH | Sept. 9, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,699,343 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,733 SH | Aug. 19, 2026 | Daily |
| ISCB · iShares Trust | · | 2,353 SH | Sept. 11, 2026 | Daily |
JBIO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 17 analysts
BUY
Median target
$47.00
+222.1%
8 47.1%
Strong Buy
8 47.1%
Buy
1 5.9%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
8 analysts · 2026-10-23Mean target $50.12 +243.6%
← Below all targets
Current price $14.59
Low$40.00
Mean$50.12
High$77.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| JBIO | $761M | -4.8 | · | · | -47.7% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | · |
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
| AVBP | $854M | -4.7 | · | · | -59.7% | · |
| CGEM | $624M | -3.2 | · | · | -44.0% | · |
| GLUE | $1.03B | · | 63.5% | -31.2% | -15.4% | · |
| ODTX | · | · | · | · | · | · |
| RIGL | $784M | 2.2 | 64.1% | 124.7% | 155.1% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 10, 2026